CHITA – a registry of in vitro NAMs
Check out the thoughtful and comprehensive review of AI in drug discovery by Andreas Bender and Isidro Cortés-Ciriano, Artificial intelligence in drug discovery: what is realistic, what are illusions? Part…
If the scientific paper is obsolete, what are we going to do about it? Despite recent efforts at modernization, the way we communicate science is broken. We can’t tell what…
In ADDC’s “Things I Wish I Knew” webinar series, we’ve been learning from prominent scientists, entrepreneurs, and investors about their successes, struggles, and the things they wished they knew before…
What are ontologies and why should I care? If you are a scientist and want your research to have long term impact, you will want to learn about ontologies and…
We’ve all been there. When reading a paper with interesting results, questions arise about some detail of the experiment. We go to the methods section for a quick check, only…
Researchers are using phenotypic assays at earlier and earlier stages of drug discovery. Assays for use in hit triage must be exceptional. In a previous post we’ve described the impact…
Where are we with validation of assays to replace animals for product testing? The short answer: not very far. While many innovative platforms with potential as animal alternatives have been…
Drug discovery practitioners are painfully familiar with “nuisance” compounds. These compounds may be screening hits that start out as promising actives but then are later discovered to be artifacts or…
Quietly happening beneath the radar, phenotypic platforms are becoming integrated into drug discovery processes. Why this is happening and how are phenotypic assays transforming the stages of drug discovery? Multiple…
A recent paper from NTP showcases the application of mechanism-based NAMs for prediction of cardiotoxic potential. In a previous post, Getting Back on Track with NAMs at FDA, we encouraged…
